Please assess the completion status of the following clinical trial:

Trial Title: A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Documentation of del (17p13.1)~* Must have relapsed or refractory CLL/SLL after receiving at least 1 prior line of systemic therapy.~* Measurable nodal disease by computed tomography (CT)~Key Exclusion Criteria:~* History or current evidence of Richter's transformation or prolymphocytic leukemia~* Prior hematologic stem cell transplantation \<6 months from study enrollment or any ongoing GVHD~* Prior exposure to ibrutinib

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ibrutinib (Type: EXPERIMENTAL): All subjects will receive ibrutnib 420 mg (3 x 140-mg capsules) orally once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).